Actively Recruiting
A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients
Led by Blokhin's Russian Cancer Research Center · Updated on 2025-12-15
60
Participants Needed
1
Research Sites
21 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation
CONDITIONS
Official Title
A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged over 18 years old
- Metastatic breast cancer including unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer
- Patients who have received Trastuzumab Deruxtecan
- Available medical history
You will not qualify if you...
- Incomplete medical history
- Pregnancy or breast-feeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation
Moscow, Russia, 115522
Actively Recruiting
Research Team
E
Elena Artamonova
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here